Literature DB >> 16439621

Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome.

Pablo Rodriguez-Viciana1, Osamu Tetsu, William E Tidyman, Anne L Estep, Brenda A Conger, Molly Santa Cruz, Frank McCormick, Katherine A Rauen.   

Abstract

Cardio-facio-cutaneous (CFC) syndrome is a sporadic developmental disorder involving characteristic craniofacial features, cardiac defects, ectodermal abnormalities, and developmental delay. We demonstrate that heterogeneous de novo missense mutations in three genes within the mitogen-activated protein kinase (MAPK) pathway cause CFC syndrome. The majority of cases (18 out of 23) are caused by mutations in BRAF, a gene frequently mutated in cancer. Of the 11 mutations identified, two result in amino acid substitutions that occur in tumors, but most are unique and suggest previously unknown mechanisms of B-Raf activation. Furthermore, three of five individuals without BRAF mutations had missense mutations in either MEK1 or MEK2, downstream effectors of B-Raf. Our findings highlight the involvement of the MAPK pathway in human development and will provide a molecular diagnosis of CFC syndrome.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16439621     DOI: 10.1126/science.1124642

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  188 in total

Review 1.  Melanoma: from mutations to medicine.

Authors:  Hensin Tsao; Lynda Chin; Levi A Garraway; David E Fisher
Journal:  Genes Dev       Date:  2012-06-01       Impact factor: 11.361

2.  Genetic inactivation of ERK1 and ERK2 in chondrocytes promotes bone growth and enlarges the spinal canal.

Authors:  Arjun Sebastian; Takehiko Matsushita; Aya Kawanami; Susan Mackem; Gary E Landreth; Shunichi Murakami
Journal:  J Orthop Res       Date:  2010-10-04       Impact factor: 3.494

3.  Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways.

Authors:  Neerav Shukla; Nabahet Ameur; Ismail Yilmaz; Khedoudja Nafa; Chyau-Yueh Lau; Angela Marchetti; Laetitia Borsu; Frederic G Barr; Marc Ladanyi
Journal:  Clin Cancer Res       Date:  2011-12-05       Impact factor: 12.531

4.  Noonan syndrome: clinical aspects and molecular pathogenesis.

Authors:  M Tartaglia; G Zampino; B D Gelb
Journal:  Mol Syndromol       Date:  2010-01-15

Review 5.  Ras and Rap signaling in synaptic plasticity and mental disorders.

Authors:  Ruth L Stornetta; J Julius Zhu
Journal:  Neuroscientist       Date:  2010-04-29       Impact factor: 7.519

Review 6.  Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale.

Authors:  Beth A Rose; Thomas Force; Yibin Wang
Journal:  Physiol Rev       Date:  2010-10       Impact factor: 37.312

7.  Genotype differences in cognitive functioning in Noonan syndrome.

Authors:  E I Pierpont; M E Pierpont; N J Mendelsohn; A E Roberts; E Tworog-Dube; M S Seidenberg
Journal:  Genes Brain Behav       Date:  2008-12-11       Impact factor: 3.449

Review 8.  Noonan syndrome caused by germline KRAS mutation in Taiwan: report of two patients and a review of the literature.

Authors:  Fu-Sung Lo; Ju-Li Lin; Min-Tzu Kuo; Pao-Chin Chiu; San-Ging Shu; Mei-Chyn Chao; Yann-Jinn Lee; Shuan-Pei Lin
Journal:  Eur J Pediatr       Date:  2008-10-29       Impact factor: 3.183

9.  p16INK4a expression and absence of activated B-RAF are independent predictors of chemosensitivity in melanoma tumors.

Authors:  Stuart J Gallagher; John F Thompson; James Indsto; Lyndee L Scurr; Margaret Lett; Bo-Fu Gao; Ruth Dunleavey; Graham J Mann; Richard F Kefford; Helen Rizos
Journal:  Neoplasia       Date:  2008-11       Impact factor: 5.715

Review 10.  Ras/MAPK syndromes and childhood hemato-oncological diseases.

Authors:  Yoko Aoki; Yoichi Matsubara
Journal:  Int J Hematol       Date:  2012-12-19       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.